Goldstraw et al. J Thorac Oncol 2007 Why should we want to screen? Survival (years)

Slides:

Advertisements

Similar presentations

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Advertisements

Helical CT Screening for Lung Cancer at Advanced Radiology Consultants

Richard F. Kucera, M.D., and David West, M.D. Pulmonary and Critical Care Associates, Greensburg, Pennsylvania INTRODUCTION CASE PRESENTATION DISCUSSION.

Joseph J. Muscato, MD, FACP Medical Director Stewart Cancer Center, Boone Hospital.

Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.

J Thorac Dis 2013;5(S5) Estimated 10 year survival 88%, regardless of treatment Survival rate 92% if surgical resection in 1 month.

Lung Cancer Screening in 2013 Cheryl Czerlanis, MD Loyola University Medical Center March 02, 2013.

NOVEMBER Lung Cancer Awareness Month. Know The Facts Second most commonly diagnosed cancer in MEN and WOMEN Most common cause of cancer death Most common.

Public Health Perspective on Radon Control in Ireland Dr. Ina Kelly Specialist Registrar in Public Health Medicine Health Service Executive Department.

G aps, challenges and opportunities Theo Verheij University Medical Center Utrecht Lower Respiratory Tract Infections in Primary Care.

4.6 Assessment of Evaluation and Treatment 2013 Analytic Lung Cancer.

Presenter Disclosure Information Diane Bild, MD, MPH Screening for Subclinical Atherosclerosis as a Strategy for CVD Prevention FINANCIAL DISCLOSURE: None.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Clinical Solutions for Lung Cancer Screening (LCS)

Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.

Criner et al. NEJM 2014: 370; 23 Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE) Presented by Ali Naqvi, MD.

Screening for Lung Cancer Jess Dalehite, M.D. Southwest Medical Imaging Midland Memorial Hospital.

Goals of Presentation Review context of lung cancer screening—why is it important? Review data from NLST supporting screening with low- dose CT (LDCT)

CRC-1 The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret.

Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.

Early Lung Cancer Screening: An Update of the Current Evidence

Gaynor Guthrie Medical Inspector

Thomas B. Newman, MD, MPH Andi Marmor, MD, MSEd October 21, 2010.

Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.

EPIB-591 Screening Jean-François Boivin 29 September

Screening Introduction to Primary Care:

Slides last updated: June 2015 CRC: CLINICAL FEATURES.

LUNG CANCER: MORE PREVALENT THAN YOU THINK Anthony D Weaver MD.

WHAT ARE THE RISK FACTORS FOR LUNG CANCER? SMOKING.

Lung Cancer Screening with Low Dose Computed Tomography Todd Robbins, MD Co-Director, Multidisciplinary Thoracic Oncology Program.

Results Recruitment 507 out of 4417 patients were eligible to take part in the study 131 of them (25.5%) participated in the study Demographics Male-female.

J. Jacques Carter, MD, MPH Assistant Professor of Medicine Department of Medicine Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts.

Implications of lung cancer screening in the new millenia Andrew R. Haas, MD, PhD Assistant Professor of Medicine Section of Interventional Pulmonary and.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

References Adherence to follow-up CT scans in patients with small pulmonary nodules, a retrospective study Sofie Lock Johansson, Niels-Chr. G. Hansen Department.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky.

Implications of lung cancer screening in the new millenia Andrew R. Haas, MD, PhD Assistant Professor of Medicine Section of Interventional Pulmonary and.

Prostate Cancer Screening Risk Management Ben Inch.

Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.

How To Design a Clinical Trial

Lung Cancer Screening: Benefits and limitations to its Implementation

OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.

[Insert Organization Name] Making the Case for Lung Cancer Screening.

REDUCED LUNG-CANCER MORTALITY WITH LOW-DOSE COMPUTED TOMOGRAPHIC SCREENING The National Lung Screening Trial Research Team N Engl J Med 2011;365:

Date of download: 5/28/2016 From: Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S.

Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.

What are the Chances Dr? Nick Pendleton. Can I have a Prostate Check? ?

Cancer Education Day Lung Cancer Screening Update Kirenza Francis, MD, FRCPC, DABR Windsor Radiological Associates May 13, 2016.

CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.

Lo Screening del Tumore Polmonare: Siamo Pronti? Mario Silva Section of Radiology, Department of Surgical Sciences University of Parma, IT bioMILD Lung.

R2 정명화 D R Baldwin, S W Duffy, N J Wald, R Page, D M Hansell,J K Field Thorax ; April 2011,Vol 66.

Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.

Diagnostic Intervals in Breast, Colorectal, Lung, Pancreatic, Oesophageal and Gastric Cancers and : Database Study Richard D NealBangor.

Benjamin Han October 12th, 2012

Making the Case for Lung Cancer Screening

Cancer prevention and early detection

Cancer Screening Guidelines

Early Detection and Screening for Lung Cancer

DETERMINING RISK FOR ASBESTOS-RELATED MALIGNANCY: LUNG CANCER

Jacob Sands, MD Dana-Farber Cancer Institute October 25, 2017

From: Use of Decision Models in the Development of Evidence-Based Clinical Preventive Services Recommendations: Methods of the U.S. Preventive Services.

Background & Objectives

Lung Cancer Screening:

Making the Case for Lung Cancer Screening

Value in Cancer Care Renato G Martins

LUNG CANCER SCREENING & SMOKING CESSATION

Lung Cancer Screening Sandra Starnes, MD Professor of Surgery

Lung Cancer screening. The NELSON trial.

Presentation transcript:

Goldstraw et al. J Thorac Oncol 2007 Why should we want to screen? Survival (years)

Why should we want to screen? Localised Regional spread Distant spread When diagnosis is based on symptoms When diagnosis is based on screening Stage shift !

National lung screening trial (NLST) Inclusion criteria -Age years -Smoking history ≥30PY, active or stopped less than 15 years ago Exclusion criteria -History of lung cancer -Other prior cancer in past 5 years -Chest CT less than 18 months ago -Unexplained weight loss (>15lb in past year) -Metallic implants or devices in chest or back -Home oxygen supplementation -Pneumonia treated with antibiotics in past 12 weeks Aberle et al. N Engl J Med 2011

-53’454 subjects randomised to one of two groups: -Low dose CT -Chest X-ray -3 screening rounds at annual intervals -Non-calcified nodules ≥4mm in CT or any size in X-ray were referred for diagnostic work-up -Primary outcome: lung cancer related mortality National lung screening trial (NLST) Aberle et al. N Engl J Med 2011

National lung screening trial (NLST)

Aberle et al. N Engl J Med 2011 National lung screening trial (NLST)

Kovalchik et al. N Engl J Med 2013 National lung screening trial (NLST)

Kovalchik et al. N Engl J Med 2013 National lung screening trial (NLST)

Lung cancer screening trials Boiselle, JAMA 2013

Screening recommendations Boiselle, JAMA 2013

Open issues -Is one positive trial enough evidence? -Was there overdiagnosis in the NSLT? -Will other populations at risk of lung cancer benefit from CT screening? -Screening of a large, at-risk population possible? -How many screening rounds? -Cost effectiveness? -«side effects» of screening (i.e.radiation exposure)

Conclusions Lung cancer is a lethal disease associated with substantial medical and economic burden. NLST: lung cancer screening may reduce mortality considerably. Possible advantage of LDCT screening has to be balanced against the potential of inducing harm. Many issues are not yet resolved: i.e. overdiagnosis, number of screening rounds, study population, cost-efficacy. Further evidence and information is needed, before lung cancer screening can be recommended in Switzerland.